Kolexia
Grivaux Michel
Pneumologie
Centre hospitalier de Meaux
Lieu inconnu
54 Activités
6 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire à petites cellules Carcinome pulmonaire non à petites cellules Carcinomes Adénocarcinome Carcinome bronchogénique Carcinome épidermoïde Perte de poids COVID-19

Industries

Boehringer Ingelheim
3 collaboration(s)
Dernière en 2017
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial.
The Lancet. Oncology   11 août 2022
Post-Surgical Non-Small Cell Lung Cancer (NSCLC) Follow-up: Multicentric Randomized Phase III Study of Post-Surgical NSCLC Follow-up
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   09 août 2022
New insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases.
Journal of thoracic disease   30 mars 2022
Erratum to "COVID-19 and medical publications: How three articles have influenced the media and public decisions in France" Rev Med Interne 42 (2021) 10.1016/j.revmed.2021.03.010.
La Revue de medecine interne   12 mai 2021
Letter to the editor regarding the article entitled "COVID-19 and medical publications: How three articles have influenced the media and public decisions in France." - Reply.
La Revue de medecine interne   07 mai 2021
COVID-19 and medical publications: How three articles have influenced the media and public decisions in France.
La Revue de medecine interne   23 mars 2021
Five-year survival and prognostic factors according to histology in 6101 non-small-cell lung cancer patients.
Respiratory medicine and research   28 octobre 2019
Metastatic NSCLC: Clinical, molecular, and therapeutic factors associated with long-term survival.
Respiratory medicine and research   10 juillet 2019
Second- or third-line treatment with erlotinib in EGFR wild-type non-small cell lung cancer: Real-life data.
Revue des maladies respiratoires   14 juin 2019
Medical journals publication: Let's change.
Revue de pneumologie clinique   11 avril 2019